Anti-VEGF Market: Global Trends, Growth Opportunities, and Future Outlook

The Anti-VEGF Market is experiencing steady growth as the prevalence of retinal diseases increases worldwide and healthcare providers adopt advanced ophthalmic therapies. According to Market Research Future, the market was valued at USD 25.98 billion in 2024 and is projected to grow from USD 27.1 billion in 2025 to USD 41.3 billion by 2035, representing a CAGR of 4.3% during the forecast period.

Anti-VEGF therapies are widely used for managing retinal conditions such as age-related macular degeneration, diabetic retinopathy, macular edema, and retinal vein occlusion. The growing aging population and increasing incidence of diabetes are contributing to demand for effective treatments. Age-related macular degeneration currently represents the largest disease segment, while diabetic retinopathy is an important emerging area.

The market includes major products such as Eylea, Lucentis, and Beovu, with Eylea identified as the dominant product segment. The emergence of biosimilars is also reshaping competition by potentially improving affordability and treatment accessibility.

North America leads the global market, accounting for more than 45% of 2024 revenue. Europe remains another significant region, while Asia-Pacific is experiencing rapid growth because of increasing healthcare expenditure, improved awareness, and a growing aging population.

Future opportunities are expected from personalized medicine, advanced drug-delivery systems, combination therapies, digital health technologies, and continued pharmaceutical innovation.